McAdam LLC Has $432,000 Holdings in Pfizer Inc. (NYSE:PFE)

McAdam LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,019 shares of the biopharmaceutical company’s stock after buying an additional 1,063 shares during the period. McAdam LLC’s holdings in Pfizer were worth $432,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in PFE. Gilbert & Cook Inc. raised its holdings in Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 945 shares in the last quarter. Eagle Wealth Strategies LLC bought a new position in shares of Pfizer in the fourth quarter worth $208,000. Silver Oak Securities Incorporated raised its stake in Pfizer by 51.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 13,368 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 4,522 shares in the last quarter. Intellectus Partners LLC lifted its position in Pfizer by 11.1% during the fourth quarter. Intellectus Partners LLC now owns 83,435 shares of the biopharmaceutical company’s stock worth $2,402,000 after purchasing an additional 8,352 shares during the period. Finally, Transcend Capital Advisors LLC grew its stake in Pfizer by 91.6% during the fourth quarter. Transcend Capital Advisors LLC now owns 121,277 shares of the biopharmaceutical company’s stock worth $3,492,000 after buying an additional 57,988 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Stock Performance

NYSE:PFE opened at $25.65 on Tuesday. The stock’s 50-day moving average is $26.92 and its 200-day moving average is $28.31. The stock has a market cap of $145.24 billion, a P/E ratio of 71.25, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.55%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is currently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.